Sandoz has received final approval for its third biosimilar, filgrastim, paving the way for this important oncology medicine to be made available to patients across the European Union. Filgrastim is indicated for the treatment of neutropenia, a condition characterized by a lack of neutrophils - one of the most common types of white blood cells - whose role is to fight infection in the body.

Novartis has gained the exclusive worldwide rights to elinogrel, a promising anti-clotting agent in Phase II clinical trials that has shown potential to offer clinical improvements over current anti-clotting medications in helping patients avoid heart attacks and strokes.

Bayer Schering Pharma AG, the pharmaceutical division of Bayer HealthCare (BHC), announced today that it will be strengthening its global Research and Development (R&D) capabilities through the foundation of a global R&D center in Beijing, China. The company will invest some 100 million Euro over the next five years to establish the center.

HemCon Medical Technologies, Inc. has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary platform technology.

The U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 that prasugrel, an investigational antiplatelet agent, should be approved for the treatment of patients with acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), Daiichi Sankyo Company, Limited, (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) announced.

Pfizer Inc announced its plans to make publicly available its compensation of U.S. healthcare professionals for consulting, speaking engagements and clinical trials. The disclosure will include payments made to practicing U.S. physicians and other healthcare providers, as well as principal investigators, major academic institutions and research sites for clinical research.

GlaxoSmithKline and Idenix Pharmaceuticals, Inc. announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being developed by Idenix for the treatment of HIV/AIDS. New NNRTIs are needed to address the increasing prevalence of viral resistance and side effects associated with this drug class.